Physician profile
Jacquelyn B Afari
NPI 1376581298
$7,471.52
in general payments reported to CMS, 2019-2025
27 companies · $1,718 in 2025
The $1,718 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $937 · 2020: $690 · 2021: $835 · 2022: $1,044 · 2023: $1,230 · 2024: $1,017 · 2025: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,965.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,434.94 | 2019-2025 | Farxiga, Tezspire, Breztri |
| Amgen INC. | $1,066.57 | 2019-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $862.51 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $723.81 | 2019-2023 | |
| Novo Nordisk INC | $610.78 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Idorsia Pharmaceuticals US INC | $524.64 | 2023-2024 | Quviviq |
| Endo Pharmaceuticals INC. | $286.07 | 2019-2022 | |
| Amarin Pharma, INC. | $277.57 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $215.52 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $194.24 | 2021-2023 | Jynarque, Nuedexta |
| Lilly USA, LLC | $188.51 | 2020-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $179.32 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $155.49 | 2020-2021 | |
| Agepha Pharma Fz LLC | $129.46 | 2024-2025 | Lodoco |
| Kowa Pharmaceuticals America, INC. | $114.88 | 2021-2024 | Livalo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $99.49 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $69.49 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.07 | 2024-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $57.72 | 2019 | |
| Avanir Pharmaceuticals, INC. | $41.45 | 2019 | |
| Xeris Pharmaceuticals, INC. | $41.39 | 2025 | Keveyis |
| Allergan, INC. | $37.58 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.79 | 2024-2025 | |
| Genzyme Corporation | $19.50 | 2022 | |
| Gilead Sciences, INC. | $17.40 | 2019 | |
| Abbott Laboratories | $16.66 | 2024 | Freestyle Libre 3 |
| Calliditas Therapeutics US INC. | $13.67 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacquelyn Afari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.